Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a further tranche of its ordinary fully paid shares as part of a previously announced capital management initiative. The daily notification shows that the company has now bought back more than 6.6 million shares in total, incrementally reducing its share count and potentially enhancing earnings per share and capital efficiency for existing investors.
The latest update, dated 26 March 2026, records 77,944 shares repurchased on the previous trading day, reflecting ongoing execution of the buy-back first notified in October 2025. Regular ASX disclosures of the daily buy-back activity signal disciplined adherence to listing rules and provide transparency to shareholders about the scale and pace of the company’s capital management strategy.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is a medical diagnostics company operating pathology laboratories and collection centres across Australia. It provides a range of clinical laboratory testing services to healthcare providers, hospitals and patients, competing in the broader healthcare and diagnostics sector on the Australian Securities Exchange under the code ACL.
Average Trading Volume: 749,142
Technical Sentiment Signal: Sell
Current Market Cap: A$370.9M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.